Are you presenting a Poster at ESMO24?
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.
This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.
If you want your poster to be featured on our website, please tag OncoDaily on LinkedIn and X.
This is part 2 of Poster Presentations from ESMO24:
“Was good to see Anis Hamid presenting the ANZUP trials ENZAMET poster alongside Samantha Oakes and Jennifer Thompson. Thanks again to all the authors, PIs and patients.”
“Amazing to be at ESMO2024 and see novel trials and development of drugs for onc patients across a wide range of malignancies, but we need patient access. Here we highlight that patients in Ireland are accessing treatments more than x2 as slow as the UK. Let’s push for change!”
“Our poster ESMO2024 (1646P): ADT + Doce + Nivo in pts with DDR-proficient & immune-cold mHSPC did not meet PSA endpoint; 3/20 pts with durable responses; post-ADT baseline CTCs indicate persistent AR signaling as resistance mechanism. Biomarker cohorts results to follow.”
“Excited to share Paulo Bergerot’s study at ESMO24! Patients undergoing treatment for metastatic cancer reported improvements in HRQOL and reduced symptom burden after a 12-week remote exercise program Promising results for Supportive Care!”
“Powerhouse AI guru Omar Khan presents his work with over 8200 Lung Cancer patients from AHS Cancer Care data warehouse creating prognostic models. Can do this in other cancers in the future now that infrastructure is primed. Stay tuned for more!!”
“ESMO ESTRO recommendations on RT Targeted agents combo.”
“Proud of these rising star in GU oncology who I am sure will make a huge impact in the treatment of our next patients with GU cancers.”
“Honored to present data on CTCs and ctDNA analysis on eBC patients!
– Low CTCs correlate with pCR regardless BC subtype
– cfDI index may be useful in predicting pCR in BC pts but we need to select pts according to BC subtypes.”
More posts featuring ESMO24 on oncodaily.com
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023